Is Sino Biopharm (1177) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.9% / 30% | 13.5% / 30% | 3.9% / 30% | 1.73% / 5% | ✓ HALAL |
| DJIM | 8.9% / 33% | 13.5% / 33% | 3.9% / 33% | 1.73% / 5% | ✓ HALAL |
| MSCI | 14.8% / 33% | 22.7% / 33% | 6.6% / 33% | 1.73% / 5% | ✓ HALAL |
| S&P | 8.9% / 33% | 13.5% / 33% | 3.9% / 33% | 1.73% / 5% | ✓ HALAL |
| FTSE | 14.8% / 33% | 22.7% / 33% | 6.6% / 50% | 1.73% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.1% | |
| Operating Margin | 20.2% | |
| Net Margin | 7.4% | |
| Return on Equity (ROE) | 12.5% | |
| Return on Assets (ROA) | 5.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $6.6B |
| Free Cash Flow | $5.2B |
| Total Debt | $9.7B |
| Debt-to-Equity | 38.2 |
| Current Ratio | 1.4 |
| Total Assets | $65.4B |
Price & Trading
| Last Close | HKD 5.82 |
| 50-Day MA | HKD 6.31 |
| 200-Day MA | HKD 6.90 |
| Avg Volume | 64.2M |
| Beta | 0.8 |
|
52-Week Range
HKD 3.18
| |
About Sino Biopharm (1177)
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Purification Calculator
As a halal stock with 1.73% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sino Biopharm (1177) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sino Biopharm is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sino Biopharm's debt ratio?
Sino Biopharm's debt ratio is 8.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.8%.
Does Sino Biopharm require dividend purification?
Yes, Sino Biopharm has an impermissible income ratio of 1.73%, which means 1.73% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Sino Biopharm's key financial metrics?
Sino Biopharm has a market capitalization of $105.3B, trailing P/E ratio of 39.3, and revenue of $28.9B. The company maintains a gross margin of 82.1% and a net margin of 7.4%. Return on equity stands at 12.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.